Abstract
A locus for familial melanoma, MLM, has been mapped within the same interval on chromosome 9p21 as the gene for a putative cell cycle regulator, p16INK4 (CDKN2) MTS1. This gene is homozygously deleted from many tumour cell lines including melanomas, suggesting that CDKN2 is a good candidate for MLM. We have analysed CDKN2 coding sequences in pedigrees segregating 9p melanoma susceptibility and 38 other melanoma-prone families. In only two families were potential predisposing mutations identified. No evidence was found for heterozygous deletions of CDKN2 in the germline of melanoma-prone individuals. The low frequency of potential predisposing mutations detected suggests that either the majority of mutations fall outside the CDKN2 coding sequence or that CDKN2 is not MLM.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
206,07 € per year
only 17,17 € per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Cannon-Albright, L.A. et al. Assignment of a locus for familial melanoma MLM, to chromosome 9p13–22. Science 258, 1148–1152 (1992).
Nancarrow, D.J. et al. Confirmation of chromosome 9p linkage in familial melanoma. Am. J. hum. Genet. 53, 936–942 (1993).
Gruis, N.A. et al. Linkage analysis in Dutch familial atypical multiple mole-melanoma (FAMMM) syndrome families. Effect on naevus count. Melanoma Res. 3, 271–277 (1993).
Goldstein, A.M. et al. Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. Am. J. hum. Genet. 54, 489–496 (1994).
Cannon-Albright, L.A. et al. Localization of the 9p melanoma susceptibility locus to a 2cM region between D9S736 and D9S171. Genomics (in the press).
Knudson, A.G. Mutation and cancer: statistical study of Retinoblastoma. Proc. natn. Acad. Sci. U.S.A. 68, 820–823 (1971).
Weaver-Feldhaus, J. et al. Localization of a putative tumor suppressor gene using homozygous deletion breakpoints in melanomas. Proc. natn. Acad. Sci. U.S.A. 91, 7563–7567 (1994).
Kamb, A. et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264, 436 (1994).
Nobori, T. et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368, 753 (1994).
Serrano, M., Hannon, G.J. & Beach, D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 366, 704, (1993).
Sherr, C.J. Mammalian G1 cyclins. Cell 73, 1059–1065 (1993).
Anderson, D.E. & Badzioch, M.D. Hereditary cutaneous malignant melanoma: A 20-year family update. Anticancer Res. 11, 433–438 (1991).
Aitken, J.F. et al. Heterogeneity of melanoma risk in families of melanoma patients. Am. J. Epidem. (in the press).
Fountain, J.W. et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc. natn. Acad. Sci. U.S.A. 89, 10557–10561 (1992).
Knudson, A.G. All in the (cancer) family. Nature Genet. 5, 103–104 (1993).
Harris, C.C. p53: at the cross roads of molecular carcinogenesis and risk assessment. Science 262, 1980 (1993).
Goldstein, A.M. et al. Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/DN) on chromosome 1p, and evidence for genetic heterogeneity. Am. J. hum. Genet. 52, 537–550 (1993).
Bale, S.J. et al. Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic naevus to chromosome 1p. New Engl. J. Med. 320, 1367–1372 (1989).
Cannon-Albright, L.A. et al. Evidence against the reported linkage to the cutaneous melanoma-dysplastic naevus syndrome locus to chromosome 1p36. Am. J. hum. Genet. 46, 912–918 (1990).
Gruis, N.A., Bergman, W. & Frants, R.R. Locus for susceptibility to melanoma on chromosome 1p. New Engl. J. Med. 322, 853–854 (1990).
Kefford, R.F., Salmon, J., Shaw, H.M., Donald, J.A. & McCarthy, W.H. Hereditary melanoma in Australia: variable association with dysplastic naevi and absence of genetic linkage to chromosome 1p. Cancer Genet. Cytogenet. 51, 45–55 (1991).
Nancarrow, D.J. et al. Exclusion of the familial melanoma locus (MLM) from the PND/D1S47 and LMYC regions of chromosome arm 1p in 7 Australian pedigrees. Genomics 12, 18–25 (1992).
van Haeringen, A. et al. Exclusion of the dysplastic naevus syndrome (DNS) locus from the short arm of chromosome 1 by linkage studies in Dutch families. Genomics 5, 61–64 (1989).
Cairns, P. et al. Rate of p16 (MTS1) mutations found in primary tumors with 9p loss. Science 265, 415–416 (1994).
Spruck, C.H. III et al. p16 gene in uncultured tumours. Nature 370, 183–184 (1994).
Takahiro, M. et al. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res. 54, 3396–3397 (1994).
Kamb, A. et al. Response to rate of p16 (MTS1) “Rate of mutations found in primary tumors with 9p loss”. Science 265, 416–417 (1994).
Bergman, W., Palan, A. & Went, L.N. Clinical and genetic studies in six Dutch kindreds with Dysplastic Naevus Syndrome. Ann. hum. Genet. 50, 249–258 (1986).
Cai, S.P. et al. Two novel beta-thalassemia mutations in the 5′ and 3′ noncoding regions of the beta-globin gene. Blood 79, 1342–1346 (1992).
Randall, T. Triplet repeat mutations: amplification within pedigrees generates three human diseases. J. Am. med. Assoc. 269, 558&562 (1993).
Sambrook, J., Fritsch, E.F. & Maniatis, T. Molecular cloning: a laboratory manual (Cold Spring Harbor Laboratory Press, Plainview, New York, 1989).
Miki, Y. et al. Disruption of the APC gene by a retrotransposal insertion of L1 sequence in a colon cancer. Cancer Res. 52, 643–645 (1992).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kamb, A., Shattuck-Eidens, D., Eeles, R. et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8, 22–26 (1994). https://doi.org/10.1038/ng0994-22
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ng0994-22
